Overview

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The outcome of patients with metastatic Ewings Sarcoma is poor with current standard of care chemotherapy, with less than 30% survival. Based on recent encouraging pediatric literature we have designed this trial to improve the outcome of patients with metastatic Ewings sarcoma using Irinotecan and Temozolomide in addition to standard chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
Amgen
Treatments:
Camptothecin
Cyclophosphamide
Dacarbazine
Doxorubicin
Irinotecan
Liposomal doxorubicin
Temozolomide
Vincristine